Pfizer and biontech granted u.s. emergency use authorization for booster dose of their covid-19 vaccine in children 5 through 11 years of age

New york & mainz, germany--(business wire)--pfizer inc. (nyse: pfe) and biontech se (nasdaq: bntx) today announced the u.s. food and drug administration (fda) expanded emergency use authorization (eua) to include a booster dose after completion of the primary series of the pfizer-biontech covid-19 vaccine in children 5 through 11 years of age. the booster dose is given at least five months after the second dose of the two-dose primary series and is the same 10-Μg dose of the pfizer-biontech cov
BNTX Ratings Summary
BNTX Quant Ranking